Oedien (Dienogest, Ethinylestradiol | Lactose)

Dienogest, the active ingredient in Oedien, is a progestogenic component of a combined oral contraceptive presented as tablets for oral use. It is paired with ethinyloestradiol to provide hormonal contraception and to manage endometriosis‑related symptoms in women of reproductive age.

GNH USA supplies Oedien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oedien, a combined oral contraceptive, is employed in hormonal regulation and reproductive health management. - Contraception: prevention of pregnancy in women of reproductive age. - Endometriosis management: reduction of pelvic pain and lesion progression. - Menstrual cycle regulation: improvement of cycle regularity and reduction of heavy bleeding.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary swelling or discomfort. - Headache: occasional mild to moderate pain. - Weight gain: slight increase in body weight. - Mood changes: fluctuations in emotional state. - Breakthrough bleeding: irregular spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Arterial thrombosis: clot formation in arteries, potentially causing stroke. - Hypertension: elevated blood pressure. - Liver disorders: jaundice or hepatic dysfunction. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Visual disturbances: sudden vision changes or loss.

Before initiating Oedien, consider the following safety measures. - Contraindications: known thrombosis, estrogen‑dependent tumor, pregnancy, severe liver disease. - Smoking: avoid use in women over 35 who smoke. - Cardiovascular risk: assess history of hypertension, stroke, or myocardial infarction. - Drug interactions: review concomitant medications that may affect efficacy. - Monitoring: periodic blood pressure and lipid profile checks recommended. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Oedien may interact with several medicines; awareness of interaction severity is essential. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive effectiveness. - Anticoagulants (e.g., warfarin): increased risk of thrombotic events. - Hepatotoxic drugs (e.g., certain antitubercular agents): heightened liver strain. Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): may increase bleeding tendency. - Anticonvulsants (e.g., phenytoin): moderate reduction in hormone levels. - Herbal supplements (e.g., St. John’s wort): potential decrease in contraceptive efficacy. - Antifungals (e.g., ketoconazole): may increase hormone concentrations. - Antibiotics (e.g., clarithromycin): possible modest effect on hormone metabolism.